These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11230879)

  • 1. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
    Maelicke A; Samochocki M; Jostock R; Fehrenbacher A; Ludwig J; Albuquerque EX; Zerlin M
    Biol Psychiatry; 2001 Feb; 49(3):279-88. PubMed ID: 11230879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
    Coyle JT; Geerts H; Sorra K; Amatniek J
    J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A; Schrattenholz A; Samochocki M; Radina M; Albuquerque EX
    Behav Brain Res; 2000 Aug; 113(1-2):199-206. PubMed ID: 10942046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
    Samochocki M; Höffle A; Fehrenbacher A; Jostock R; Ludwig J; Christner C; Radina M; Zerlin M; Ullmer C; Pereira EF; Lübbert H; Albuquerque EX; Maelicke A
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1024-36. PubMed ID: 12649296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinic cholinergic modulation: galantamine as a prototype.
    Woodruff-Pak DS; Lander C; Geerts H
    CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease.
    Coyle J; Kershaw P
    Biol Psychiatry; 2001 Feb; 49(3):289-99. PubMed ID: 11230880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A; Albuquerque EX
    Eur J Pharmacol; 2000 Mar; 393(1-3):165-70. PubMed ID: 10771010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.
    Akk G; Steinbach JH
    J Neurosci; 2005 Feb; 25(8):1992-2001. PubMed ID: 15728839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR.
    Samochocki M; Zerlin M; Jostock R; Groot Kormelink PJ; Luyten WH; Albuquerque EX; Maelicke A
    Acta Neurol Scand Suppl; 2000; 176():68-73. PubMed ID: 11261808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy.
    Geerts H; Finkel L; Carr R; Spiros A
    J Neural Transm Suppl; 2002; (62):203-16. PubMed ID: 12456064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.
    Maelicke A
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.
    Ludwig J; Höffle-Maas A; Samochocki M; Luttmann E; Albuquerque EX; Fels G; Maelicke A
    J Recept Signal Transduct Res; 2010 Dec; 30(6):469-83. PubMed ID: 21062106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
    Lilienfeld S
    CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
    Santos MD; Alkondon M; Pereira EF; Aracava Y; Eisenberg HM; Maelicke A; Albuquerque EX
    Mol Pharmacol; 2002 May; 61(5):1222-34. PubMed ID: 11961141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.
    Texidó L; Ros E; Martín-Satué M; López S; Aleu J; Marsal J; Solsona C
    Br J Pharmacol; 2005 Jul; 145(5):672-8. PubMed ID: 15834443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.